A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer(†)

BACKGROUND: Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) and phosphoinositide 3-kinase (PI3K), has shown efficacy in preclinical pancreatic cancer models. In this study, rigosertib was assessed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Oncol
Autori principali: O'Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J., Coveler, L., Olowokure, O. O., Baranda, J. C., Cusnir, M., Phillip, P., Boles, J., Nazemzadeh, R., Rarick, M., Cohen, D. J., Radford, J., Fehrenbacher, L., Bajaj, R., Bathini, V., Fanta, P., Berlin, J., McRee, A. J., Maguire, R., Wilhelm, F., Maniar, M., Jimeno, A., Gomes, C. L., Messersmith, W. A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2015
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4551155/
https://ncbi.nlm.nih.gov/pubmed/26091808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv264
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi